Other - Kava extract versus placebo for treating anxiety (Meta-analysis)

[Bajeda]

Authors: M.H. Pittler & E. Ernst.
Title: Kava extract versus placebo for treating anxiety.
Source: Cochrane Database of Systematic Reviews. 3, 2009.
Date of Most Recent Amendment: 11-01-2008
Date of Most Recent Substantive Amendment: 11-17-2002


Background

Constraints on resources and time often render treatments for anxiety such as psychological interventions impracticable. While synthetic anxiolytic drugs are effective, they are often burdened with adverse events. Other options which are effective and safe are of considerable interest and a welcome addition to the therapeutic repertoire.


Objectives

To assess the effectiveness and safety as reported in rigorous clinical trials of kava extract compared with placebo for treating anxiety.


Search strategy

All publications describing (or which might describe) randomised, double-blind, placebo-controlled trials of kava extract for anxiety were sought through electronic searches on EMBASE (1974 to January 2005), MEDLINE (1951 to January 2005), AMED (1985 to January 2005)), CISCOM (inception until August 2002) and Central/CCTR and CCDANCTR (issue 1, 2005). The search terms that were used were kava, kawa, kavain, Piper methysticum and Rauschpfeffer (German common name for Piper methysticum). Additionally, manufacturers of kava preparations and experts on the subject were contacted and asked to contribute published and unpublished material. Hand-searches of a sample of relevant medical journals (Erfahrungsheilkunde 1996 - 2005, Forsch Komplementarmed Klass Naturheilkd 1994 - 2005, Phytomed 1994 - 2005, Alt Comp Ther 1995 - 2005), conference proceedings (e.g. FACT - Focus on Alternative and Complementary Therapies 1996 - 2005) and our own collection of papers were conducted. No restrictions regarding the language of publication were imposed.


Selection criteria

To be included studies were required to be randomised, controlled trials (RCTs), i.e. trials with a randomised generation of allocation sequences, and conducted placebo-controlled and double-blind, i.e. trials with blinding of patients and care providers. Trials using oral preparations containing kava extract as the only component (mono-preparation) were considered. Trials using single constituents of kava extract alone, assessing kava extract as one of several active components in a combination preparation or as a part of a combination therapy were excluded.


Data collection and analysis

Data were extracted systematically according to patient characteristics, interventions and results. Methodological quality of all trials was evaluated using the standard scoring system developed by Jadad and colleagues. The screening of studies, selection, data extraction, validation and the assessment of methodological quality were performed independently by the two reviewers. Disagreements in the evaluation of individual trials were largely due to reading errors and were resolved through discussion.


Main results

Twelve double-blind RCTs (n=700) met the inclusion criteria. The meta-analysis was done on seven studies using the total score on the Hamilton Anxiety (HAM-A) scale as a common outcome measure. The result suggests a significant effect towards a reduction of the HAM-A total score in patients receiving kava extract compared with patients receiving placebo (weighted mean difference: 3.9, 95% confidence interval: 0.1 to 7.7; p = 0.05; n = 380). The results of the five studies that were not submitted to meta-analysis largely support these findings. Adverse events as reported in the reviewed trials were mild, transient and infrequent.


Authors' conclusions

Compared with placebo, kava extract is an effective symptomatic treatment for anxiety although, at present, the size of the effect seems small. The effect lacks robustness and is based on a relatively small sample. The data available from the reviewed studies suggest that kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required. Rigorous trials with large sample sizes are needed to clarify the existing uncertainties. Also, long-term safety studies of kava are required.




References

Bhate, H, Gerster, G, Gracza, E, Orale Pramedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanasthesie Erfahrungsheilkunde 1989 38

Connor, KM, Davidson, JR, A placebo-controlled study of kava kava in generalized anxiety disorder International Clinical Psychopharmacology 2002 17

Gastpar, M, Klimm, HD, Treatment of anxiety, tension and restlessness states with kava special extract WS1490 in general practice: A randomized placebo-controlled double-blind multicenter trial Phytomedicine 2003 20

Geier, FP, Konstantinowicz, T, Kava treatment in patients with anxiety Phytotherapy Research 2004 18

Kinzler, E, Kromer, J, Lehmann, E, Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis Double blind study with placebos over 4 weeks [Wirksamkeit eines Kava-Spezial-Extraktes bei Patieinten mit Angst-, Spannungs- und Erregungszustanden nicht-psychotischer Genese] Arzneimittelforschung 1991 41

Lehmann, E, Wirkung bei Kava - Kava bei akuter Angst Synopsis 1998 2

Lehrl, S, Clinical efficacy of kava extract WS1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter randomized placebo-controlled double-blind clinical trial Journal of Affective Disorders 2004 78

Malsch, U, Kieser, M, Efficacy of kava-kava in the treamtent of non-psychotic anxiety, following pretreatment with benzodiazepines Psychopharmacology 2001 157

Singh, NN, Ellis, CR, Sharp, I, Eakin, K, Best, AM, Singh, YN, A double-blind, placebo-controlled study of the effects of kava (Kavatrol) on daily stress and anxiety in adults Alternative Therapies (Natrol in-house publication 1997) 1998 4

Volz, HP, Kieser, M, Kava-kava extract WS1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial PharmacopsychiatRY 1997 30

Warnecke, G, Pfaender, H, Gerster, G, Gracza, E, Efficacy of an extract of Kavaroot in patients with climacteric syndrome [Wirksamkeit von Kawa-Kawa-Extrakt beim klimakterischen Syndrom] Zeitschrift fur Phytotherapie 1990 11

Warnecke, G, Psychosomatic dysfunctions in the female climacteric Clinical effectiveness and tolerance of Kava Extract WS-1490 [Psychosomatische Dysfunktionen im weiblichen Klimakterium Klinische Wirksamkeit und Vertraglichkeit von KavaExtrakt WS 1490] Fortschritte der Medizin 1991 109

Bhate, H, Gerster, G, Behandlung mit Phytotranquilizern vor der Narkose Therapeutikon 1992 6

De Leo, V, La Marca, A, Morgante, G, Lanzetta, D, Floria, P, Petraglia, F, Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety Maturitas 2001 39

Lehmann, E, Klieser, E, Klimke, A, Krach, H, Spatz, R, The efficacy of cavain in patients suffering from anxiety Pharmacopsychiatry 1989 22.

Lehmann, E, Kinzler, E, Friedmann, J, Efficacy of a special kava extract (Piper methysticum) in patients with states of anxiety, tension and exitedness of non-mental origin - a double-blind placebo-controlled study of four weeks treatment Phytomedicine 1996 3

Lindenberg, D, Pitule-Schodel, H, D,L-kavain in comparison with oxazepam in anxiety disorders A double-blind study of clinical effectiveness [D,L-Kavain im Vergleich zu Oxazepam bei Angstzustanden. Doppelblindstudie aur Wirksamkeit] Fortschritte der Medizin 1990 108

Moller, HJ, Heuberger, L, Anxiolytic potency of D,L-kavain. Results of a placebo-controlled, double-blind study [Anxiolytische Potenz von D,L-Kavain] Munchener Medizinische Wochenschrift 1989 131

Moller, HJ, Ulm, K, Gloggler, A, Kavain as an aid in the withdrawal of benzodiazepines (Therapy study) [Kavain als Hilfe beim Benzodiazepin-Entzug] Munchener Medizinische Wochenschrift 1992 134

Staedt, U, Holm, E, Heep, J, Riesmuller, S, Kortsik, C, Steiner, G, Studies on effects of D,L-Kawain-psychometry, EEG and Hamilton scale [Zum Wirkungsprofil von D,L-Kavain] Medizinische Welt 1991 42

Warnecke, G, Gerster, G, Jager, H, Anxiolytic effect with a phytotranquilizer in gynecology [Anxiolyse mit einem Phyto-Tranquilizer in der Frauenheilkunde] Medizinische Welt 1986 37

Warnecke, G, Langzeittherapie psychischer und vegetativer Dysrepulationen mit Zubereitungen aus Piper methysticum Erfahrungsheilkunde 1989 38

Astin, JA, Why patients use alternative Medicine. Results of a national study JAMA 1998 279

Barbone, F, McMahon, AD, Davey, PG, Morris, AD, Reid, IC, McDevitt, DG, Association of road-traffic accidents with benzodiazepine use Lancet 1998 352

Blumenthal, M, Herb sales down 15 percent in mainstream market Herbalgram 2001 51

Boerner, RJ, Sommer, H, Berger, W, Kuhn, U, Schmidt, U, Mannel, M, Kava kava extract LI150 is as effective as opipramol and buspirone in generalized anxiety disorder - An 8-week randomized double-blind multi-centre clinical trial in 129 out-patients Phytomedicine 2003 10

Brevoort, P, The booming US botanical market - a new overview Herbalgram 1998 44

Cawte, J, Psychoactive substances of the south seas: betel, kava and pituri Australian and New Zealand Journal of Psychiatry 1985 19

Chrubasik, S, Klinisch geprufte Wirksamkeit bei nervosen Angst-, Spannungs- und Unruhezustanden Der Allgemeinarzt 1997 18

Connor, KM, Davidson, JR, Churchill, LE, Adverse-effect profile of kava CNS Spectrum 2001 6

Deans, HG, Skinner, P, Doctors' views on anxiety management in general practice Journal of the Royal Society of Medicine 1992 85

Easterbrook, PJ, Berlin, JA, Gopalan, R, Matthews, DR, Publication bias in clinical research Lancet 1991 337

Egger, M, Zellweger-Zahner, T, Schneider, M, Junker, C, Lengeler, C, Antes, G, Language bias in randomised controlled trials published in English and German Lancet 1997 350

Egger, M, Smith, GD, Bias in location and selection of studies BMJ 1998 316

Ernst, E, Pittler, MH, Alternative therapy bias Nature 1997 385

Gorman, JM, Papp, LA, Chronic anxiety: deciding the lenght of treatment Journal of Clinical Psychiatry 1990 51

Greenberg, PE, Sisitsky, T, Kessler, RC, Finkelstein, SN, Berndt, ER, Davidson, JR, The economic burden of anxiety disorders in the 1990s Journal of Clinical Psychiatry 1999 60

Habs, M, Honold, E, Der psychoaktive Spezialextrakt WS 1490 aus dem Wurzelstock von Piper methysticum (Kava-Kava) - ein Report Forschende Komplementarmedizin 1994 1

Hofmann, R, Winter, U, Therapeutische Moglichkeiten mit Kava-Kava bei Angsterkrankungen Psycho 1996 22

Hunt, C, Singh, M, Generalized anxiety disorder International Review of Psychiatry 1991 3

Hansel R, Kammerer S. Kava-Kava. Basel: Aesopus, 1996.

Jadad, AR, Moore, A, Carroll, D Jenkinson C, Reynolds, DJ, Gavaghan, DJ, Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Controlled Clinical Trials 1996 17

Jorm, AF, Christensen, H, Griffiths, KM, Parslow, RA, Rodgers, RA, Blewitt, KA, Effectiveness of complementary and self-help treatments for anxiety disorders MJA 2004 181

Kessler, RC, McGonagle, KA, Zhao, S, Nelson, CB, Hughes, M, Eshleman, S, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States Archives of General Psychiatry 1994 51

Kessler, RC, Soukup, J, Davis, RB, Foster, DF, Wilkey, SA, Van Rompay, MI, The use of complementary and alternative therapies to treat anxiety and depression in the United States American Journal of Psychiatry 2001 158

Lebot V, Merlin M, Lindstrom L. Kava, the pacific drug. New Haven, CT: Yale University Press, 1992.

Lemert, EM, Secular use of kava in Tonga Journal of Ethnopharmacology 1967 28

Melville H. Typee: a peep at Polynesian life during a four months' residence in a valley of the Marquesas. New York, NY: Signet, 1964.

Moore, A, McQuay, H, Muir Gray, JA, Benzodiazepines and car crashes Bandolier 1998 57

Myers, JK, Weissman, MM, Tischler, GL, Holzer, CE, Leaf, PJ, Orvaschel, H, Six-month prevalence of psychiatric disorders in three communities 1980 to 1982 Archives of General Psychiatry 1984 41

Nieminen, P, Isohanni, M, Bias against European journals in medical publication databases Lancet 1999 353

O'Neill, D, Benzodiazepines and driver safety Lancet 1998 352

Pittler, MH, Ernst, E, Efficacy of kava extract for treating anxiety: systematic review and meta-analysis Journal of Clinical Psychopharmacology 2000 20

Pittler, MH, Abbot, NC, Harkness, EF, Ernst, E, Location bias in controlled clinical trials of complementary/alternative therapies Journal of Clinical Epidemiology 2000 53

Priest, RG, Montgomery, SA, Benodiazepines and dependence: a college statement Bulletin of the Royal College of Psychiatrists 1988 12

Robinson, MD, Anxiety disorders in the general practice New Jersey medicine: the journal of the Medical Society of New Jersey 1993 90

Schmidt, K, Pittler, MH, Ernst, E, Bias in alternative medicine is still rife but is diminishing BMJ 2001 323

Schulze, J, Raasch, W, Siegers, CP, Toxicity of kava pyrones, drug safety and precautions - a case study Phytomedicine 2003 10

Siegers, CP, Honold, E, Krall, B, Meng, G, Habs, M, Ergebnisse einer Anwendungsbeobachtung L1090 mit Laitan(R) Kapseln Arztliche Forschung 1992 39

Singh, YN, Blumenthal, M, Kava, an overview Herbalgram 1998 39

Spree, MH, Croy, HH, Antares - ein standardisiertes Kava-Kava Praparat mit dem Spezialextrakt KW 1491 Der Kassenarzt 1992 17

Stevinson, C, Huntley, A, Ernst, A systematic review of the safety of kava extract in the treatment of anxiety Drug Safety 2002 25

Teschke, R, Gaus, W, Loew, D, Kava extracts: Safety and risks including rare hepatoxicity Phytomedicine 2003 10

Unger, L, Veranderung psychovegetativer Beschwerden unter Therapie mit Kavain Therapiewoche 1988 38

Walley, EJ, Beebe, DK, Clark, JL, Management of common anxiety disorders American Family Physician 1994 50

Weber, U, Winter, U, Kava-Kava - ein pflanzliches Anxiolytikum Fundamenta Psychiatrica 1994 8

Woelk, H, Kapoula, O, Lehrl, S, Schroter, K, Weinholz, P, Behandlung von Angst-Patienten Zeitschrift fuer Allgemeinmedizin 1993 69

Reputation Comments on this post:

pretty fascinating read, great to see such research is being done